To validate and confirm whether these patient-derived NSCLC xenograft models showed similar responses to gefitinib treatment as compared to that reported in clinical trials, eight of the ten established xenograft models were treated with the EGFR tyrosine kinase inhibitor gefitinib (Table 3 and Figure 3). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.